Sun Pharmaceutical Industries logo

Sun Pharmaceutical Industries financials and balance sheet

NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap

Formerly Sun Pharmaceuticals Industries
Last close ₹1,748.00down ₹10.00 (0.57%)BSE ₹1,743.00

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,758.00.

52-week range of traded prices to 23 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
Market cap
₹4,19,404 Cr13th largest listed
P/E
34.7
P/B
5.0
Dividend yield
0.92%
ROE
15.5%
ROCE
16.9%
Debt to equity
0.05
Volume, NSE
10,64,52860.0% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Sun Pharmaceutical Industries annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹58,462 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.2% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue58,462
  2. Materials and goods−11,544
  3. Employee costs−11,419
  4. Other expenses−17,768
  5. Operating profit17,731
  6. Depreciation−2,938
  7. Other income+1,972
  8. One-off items−1,307
  9. Finance costs−339
  10. Profit before tax15,119
  11. Tax−3,554
  12. Joint ventures−56
  13. Net profit11,509

What the company owns

  • Plant, investments and other assets₹49,246 Cr
  • Current investments₹20,933 Cr
  • Receivables₹15,510 Cr
  • Cash and bank₹11,603 Cr
  • Inventory₹11,493 Cr

What pays for it: net worth and liabilities

  • Net worth₹83,880 Cr
  • Other liabilities₹13,490 Cr
  • Owed to suppliers₹7,334 Cr
  • Borrowings₹4,082 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Sun Pharmaceutical Industries quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 28 MayMar 2021Filed 28 MayMar 2022Filed 31 MayMar 2023Filed 26 MayMar 2024Filed 23 MayMar 2025Filed 12 JunMar 2026Filed 22 May
Revenue from operations31,57826,48929,06632,83833,49838,65443,88648,49752,57858,462
21,48920,88122,75825,84825,00728,25732,23935,47437,30740,731
Materials and goods bought8,1317,4257,8699,2308,69010,35210,66210,66310,74711,544
Employee costs4,9025,3675,9676,3626,8627,3018,2969,4299,97311,419
Other expenses8,4568,0908,92210,2559,45410,60413,28115,38216,58617,768
Operating profit before depreciation10,0895,6086,3086,9908,49110,39811,64713,02315,27217,731
Operating margin31.9%21.2%21.7%21.3%25.3%26.9%26.5%26.9%29.0%30.3%
Materials, % of revenue25.7%28.0%27.1%28.1%25.9%26.8%24.3%22.0%20.4%19.7%
Employee costs, % of revenue15.5%20.3%20.5%19.4%20.5%18.9%18.9%19.4%19.0%19.5%
Other expenses, % of revenue26.8%30.5%30.7%31.2%28.2%27.4%30.3%31.7%31.5%30.4%
Depreciation and amortisation1,2651,5001,7532,0532,0802,1442,5292,5572,5752,938
Operating profit after depreciation8,8254,1084,5544,9376,4118,2549,11710,46612,69614,794
Other income6238391,0256368369226351,3541,9651,972
Finance costs400518555303141127172238231339
Profit before one-off items and tax9,0484,4295,0255,2707,1069,0489,58011,58214,43016,426
One-off items0−951−1,214−261−4,306−4,567−171−494−678−1,307
Profit before tax9,0483,4793,8105,0102,7994,4819,40811,08813,75215,119
1,2128456018235151,0768481,4392,7723,554
Share of profit of joint ventures and associates10−25−1−15−12−17−48−38−15−56
7,8462,6083,2084,1722,2723,3898,5139,61010,96511,509
Other comprehensive income––1,6802,121−1465572,2571,1429123,827
Total comprehensive income––4,8886,2932,1263,94610,77010,75211,87715,335
Net margin24.8%9.8%11.0%12.7%6.8%8.8%19.4%19.8%20.9%19.7%
Net margin without joint ventures and associates24.8%9.9%11.0%12.8%6.8%8.8%19.5%19.9%20.9%19.8%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 29 MayMar 2020Filed 28 MayMar 2021Filed 28 MayMar 2022Filed 31 MayMar 2023Filed 26 MayMar 2024Filed 23 MayMar 2025Filed 12 JunMar 2026Filed 22 May
44,72349,12549,48051,06659,31567,10672,48683,880
41,40945,26446,46348,01155,99563,66772,21883,570
Share capital240240240240240240240240
Reserves41,16945,02546,22347,77155,75563,42771,97883,330
Belonging to outside owners of subsidiaries3,3143,8603,0173,0553,3203,439268310
9,8937,5783,3439316,1982,8461,8704,082
17,34015,70616,14617,20119,90616,98418,19422,622
2,6323,4212,0411,5331,5211,3731,4202,283
Liabilities going with businesses held for sale––––11––
64,69468,25267,66769,80080,74485,46392,1011,08,785
33,62536,59837,22534,78540,86041,98839,47644,894
31,06931,65430,44235,01539,86243,43352,59463,860
Net debt−1,333−3,807−6,233−11,737−8,945−16,260−23,118−28,455
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 28 MayMar 2022Filed 31 MayMar 2023Filed 26 MayMar 2024Filed 23 MayMar 2025Filed 12 JunMar 2026Filed 22 May
6,1708,9854,95912,13514,07212,419
7,1738,0156,46913,70414,54914,733
2,5641,559−5,6621,062−324−1,268
Receivables94−1,342−953353−1,602−2,009
Inventories−1,080307−1,202599−184−52
Payables3813701,1822505281,057
Other working capital3,1692,224−4,689−139934−264
Tax paid−1,003969−1,510−1,569−477−2,314
Capital spending1,1701,4952,0862,2022,1293,609
Free cash flow5,0007,4902,8749,93311,9448,810
536−5,725−7,944−690−5,306−11,344
−5,980−5,1932,376−6,710−7,906−2,513
Dividends paid1,5862,1692,5202,9013,6173,938
Shares bought back18500000
Shares issued000000
Net change in cash726−1,934−6084,735860−1,437
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Sun Pharmaceutical Industries dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 28 MayMar 2021Filed 28 MayMar 2022Filed 31 MayMar 2023Filed 26 MayMar 2024Filed 23 MayMar 2025Filed 12 JunMar 2026Filed 22 May
Earnings per share₹29.00₹9.00₹11.11₹15.69₹12.10₹13.60₹35.30₹39.90₹45.60₹47.80
Diluted earnings per share₹29.00₹9.00₹11.11₹15.69₹12.10₹13.60₹35.30₹39.90₹45.60₹47.80
Dividend per share₹3.50₹2.00₹2.75₹4.00₹7.50₹10.00₹11.50₹13.50₹16.00₹16.00
Book value per share––₹172.59₹188.66₹193.65₹200.11₹233.38₹265.35₹300.99₹348.31
Dividend payout12.1%22.2%24.8%25.5%62.0%73.3%32.6%33.8%35.1%33.4%
Shareholder yield––––1.2%1.0%1.1%0.7%0.9%0.9%
Market cap at the year end (₹ crore)1,65,1061,18,7901,14,89284,5291,43,4322,19,4792,35,8793,88,8244,16,2134,21,611
RatioMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 28 MayMar 2021Filed 28 MayMar 2022Filed 31 MayMar 2023Filed 26 MayMar 2024Filed 23 MayMar 2025Filed 12 JunMar 2026Filed 22 May
Revenue growth11.7%−16.1%9.7%13.0%2.0%15.4%13.5%10.5%8.4%11.2%
Operating profit growth19.0%−44.4%12.5%10.8%21.5%22.5%12.0%11.8%17.3%16.1%
Net profit growth66.4%−66.8%23.0%30.1%−45.5%49.2%151.2%12.9%14.1%5.0%
Earnings per share growth–−69.0%23.4%41.2%−22.9%12.4%159.6%13.0%14.3%4.8%
––6.4%8.7%6.3%6.9%16.3%16.0%16.1%14.7%
–––2.3 pts−2.4 pts0.6 pts9.4 pts−0.3 pts0.1 pts−1.3 pts
From the net margin–––1.6 pts−2.1 pts−0.1 pts8.9 pts0.4 pts0.8 pts−0.9 pts
From asset turnover–––0.8 pts0.0 pts0.9 pts0.6 pts0.0 pts0.2 pts−0.3 pts
From borrowing–––−0.2 pts−0.2 pts−0.1 pts−0.1 pts−0.7 pts−1.0 pts−0.2 pts
Return on capital employed––8.3%8.7%12.1%15.9%13.9%15.0%17.1%16.8%
Cash conversion––––271.5%265.1%58.3%126.3%128.3%107.9%
Interest cover22.17.98.216.345.364.853.043.954.943.7
Debt to equity––0.220.150.070.020.100.040.030.05
Receivable days––1121059910095859197
Inventory days––366311378317360338348363
Payable days––192162167158194194210232
Cash conversion cycle, days––285254310259261229228228
Working capital days––137112785592777880
Asset turnover––0.450.490.490.560.580.580.590.58
Assets per rupee of net worth––1.561.531.481.461.451.391.311.29
Sales per rupee of plant––2.903.113.273.734.224.765.245.26
Capital spending to depreciation––––0.560.700.820.860.831.23
Plant being built, % of plant in use––9.1%6.2%9.2%7.7%9.3%10.9%12.3%12.4%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
11.4%
Cash from operations against operating profit
70.0%
Measure10 years5 years3 years
Revenue growth, yearly rate7.5%11.8%10.0%
Profit growth, yearly rate9.3%31.6%10.6%
Return on equity, average–14.0%15.6%
Return on capital employed, average–15.7%16.3%
Operating margin, average26.1%27.9%28.7%
Net margin, average15.4%17.7%20.1%
Asset turnover, average–0.580.59
Cash conversion cycle, days, average–241229
Interest cover, average36.052.047.5
Debt to equity, average–0.050.04

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations52,57038,62612,419
Cash from investing−31,009−17,340−11,344
Cash from financing−19,946−17,129−2,513
Capital spending11,5207,9403,609
Dividends paid15,14510,4563,938
Shares bought back000
Shares issued for cash000
Borrowings raised23,21613,3995,322
Borrowings repaid23,23115,9083,410

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––687686
Altman Z-scorePublished threshold 1.81––5.274.596.589.078.8015.1215.3512.69
Beneish M-scorePublished threshold −1.78––––−2.75−2.70−2.27−2.57−2.53−2.40
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−6.520.1915.27−2.212.4810.39
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.421.211.071.20
Receivables growth less revenue growthOur threshold 0 percentage points–––−6.93−5.831.51−5.55−12.167.567.69
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−17.4420.10−19.1213.85−6.143.014.79
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.19−0.22−0.420.310.862.140.00
Assets under construction, years of additionsOur threshold 2 years of additions–––0.250.540.350.380.470.510.34
Effective tax ratePublished threshold 17.16 per cent13.3924.2915.7716.4218.3924.009.0112.9820.1623.51
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––2.37−7.04−1.1716.698.20
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
13 Oct 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleCrisil AAARatings ReaffirmedStable42
13 Oct 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesShort-term scaleCrisil A1+Ratings Reaffirmed15
13 Oct 2026CRISIL Ratings Limited (opens in a new tab)Non Convertible DebenturesLong-term scaleCrisil AAARatings AssignedStable15,000
13 Oct 2026CRISIL Ratings Limited (opens in a new tab)Commercial PaperShort-term scaleCrisil A1+Ratings Reaffirmed4,000
13 Oct 2026ICRA Limited (opens in a new tab)Non Convertible DebenturesLong-term scale[ICRA]AAANew, NewStable15,000
13 Oct 2026ICRA Limited (opens in a new tab)Commercial PaperShort-term scale[ICRA]A1+Review, Re-affirm4,000
13 Oct 2026ICRA Limited (opens in a new tab)Fund-based/Non-fund based-OthersLong and short-term scales[ICRA]AAA /[ICRA]A1+Review, Re-affirmStable5,000
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.